成骨不全
医学
骨质疏松症
双膦酸盐
骨重建
骨吸收
内科学
骨矿物
出处
期刊:Clinical calcium
日期:2010-06-01
卷期号:20 (6): 918-924
被引量:3
摘要
Osteogenesis imperfecta (OI) is a genetic disorder characterized by fragile bone and reduced bone mineral density. Cyclic intravenous pamidronate is now the most widely used treatment for moderate to severe forms of OI. Oral bisphosphonates provide clinical benefit and convenience to the patients with mild form of OI. Recently, some studies demonstrated that intravenous zolendronate in children with OI is safe in short-term and similarly effective to parmidronate. Optimal dose, duration of treatment and long-term safety of newer bisphosphonates require further investigations.
科研通智能强力驱动
Strongly Powered by AbleSci AI